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Introduction 
The atherosclerotic process is driven by a complex interplay of 
a multitude of risk factors through modulation of inflammatory, 
lipid, and immune mechanisms [1]. Smoking is perceived as a major 
cardiovascular risk factor along with diabetes, hypertension and 
hypercholesterolemia, being responsible for approximately 25% of 
cardiovascular deaths in USA and Europe [2]. Even environmental 
tobacco smoke exposure correlates with the magnitude of atherogenic 
changes in peripheral arteries [3]. Smoking has been regarded to 
diminish microcirculatory blood flow thereby reducing the oxygen 
availability in tissues leading to damage [4]. Furthermore, smoking has 
been considered to increase the amounts of inflammatory mediators 
such as reactive oxygen species, various cytokines and chemokines 
and proteolytic enzymes, such as matrix metallo proteinases (MMPs) 
and elastases in the affected tissues [5]. Thus by generating a circulus 
vitiosus of proinflammatory mediators, smoking can promote 
proinflammatory tissue destruction [6]. Smoking also intensifies the 
oxidative modification of low density lipoproteins (LDL), thereby 
increasing the atherogenic proinflammatory burden in the arterial wall 
[7]. 
MMPs form an enzyme superfamily of at least 23 genetically 
distinct but structurally related proteases [8]. The delicate balance 
between MMPs and tissue inhibitors of matrix metalloproteinases 
(TIMPs) regulates the degradation of extracellular matrix and 
basement membrane components [9]. Additionally MMPs process 
non-matrix bioactive substrates such as cytokines, chemokines, cell 
surface receptors and growth factors exerting potential to regulate 
immune and inflammatory responses [10]. Thus MMPs can act both 
surrogate by promoting protective tissue destruction or defensively 
providing anti-inflammatory shield [11]. 
Serum and plasma MMP-8 levels together with its major inhibitor 
TIMP-1 have been demonstrated to reflect disease severity and 
plaque instability in cardiovascular diseases (CVD) [12]. Our earlier 
study shows that MMP-8 and MMP-8/TIMP-1 concentrations are 
increased during ACS [13] and prevalent CVD as well as subclinical 
atherosclerosis [14]. High MMP-8 predicts all incident CVD events 
[14,15], but associates especially with CVD death in men with subclinical 
atherosclerosis in a 10-year follow-up [14]. TIMP-1 concentration 
is an independent predictor of cardiovascular death in patients with 
prevalent CVD including coronary artery disease, chronic heart failure, 
or ACS [13,16,17].
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Abstract
Background: Smoking has been perceived to increase the levels of carcinogenic and inflammatory mediators 
thereby promoting presumably malignant and proinflammatory tissue destruction via activating proteolytic enzymes 
such as matrix metalloproteinases (MMPs) and their regulators. We studied the effect of smoking on the diagnostic 
ability of serum MMP-8-IFMA and TIMP-1-ELISA analysis to recognize patients with acute coronary syndrome 
(ACS).
Methods: The case-control population (n=605) comprised 291 patients with diagnosed acute myocardial 
infarction (AMI) or unstable angina pectoris (UAP) and 314 healthy control individuals. The case and the control 
group included 55 and 66 smoking subjects, respectively.
Results: Smoking increased the MMP-8, but not the TIMP-1, concentration in both the control and the AMI 
group. MMP-8 concentration, and consequently MMP-8/TIMP-1, distinguished the cases from the controls accurately 
in the ROC analysis, but smoking decreased the AUCs in every category. The MMP-8 concentration produced an 
AUC (95% CI, p-value) for ACS of 0.771 (0.723-0.818, p<0.001) and 0.684 (0.581-0.787, p=0.001) for non-smokers 
and smokers, respectively. Similarly, the multivariate logistic regression model indicated that smoking decreased the 
association of MMP-8 with ACS. The OR (95% CI, p-value) of MMP-8 for ACS was 8.1 (per ng/ml log-transformed 
unit increase, 5.0-13.1, p<0.001) and 2.8 (1.1-7.0, p=0.025) for non-smokers and smokers, respectively.
Conclusions: One of the most important risk factors for ACS, smoking, decreases the diagnostic ability of MMP-
8 concentration and MMP-8/TIMP-1 ratio. This must be taken account if these serum determinations are used as 
biomarkers of the risk for cardiovascular diseases.
Citation: Lahdentausta L, Sorsa T, Pussinen PJ, Pesonen E (2013) The Effect of Smoking on Diagnostic Value of Serum Matrix Metalloproteinase-8 
in Acute Coronary Syndrome. J Mol Biomark Diagn S4: 002. doi:10.4172/2155-9929.S4-002
Page 2 of 5
 J Mol Biomark Diagn      Protein & Prognostic Biomarkers           ISSN: 2155-9929 JMBD, an open access journal 
Finding new biomarkers for fatal CVD events is highly important. 
MMP-8 may be regarded as such, and therefore exploring factors 
affecting its diagnostic ability is valuable. With this background we 
studied in case-control setting the effect of smoking on serum MMP-8 
and TIMP-1 concentration in ACS. 
Methods
Subjects and diagnosis
The inclusion criteria for the whole population (n=605) were 
age under 80 years and no signs of cognitive intellectual disability. 
The participants completed a questionnaire on general background 
characteristics and demographic data. The study complies with 
the Declaration of Helsinki, and the ethical committee of the Lund 
University approved it. A written informed consent was obtained from 
the subjects.
Cases consisted of 291 patients, who were admitted for ACS to 
the heart intensive care unit in Lund University Hospital between 
March 1999 and April 2002 as described earlier in detail [13,18].  Acute 
myocardial infarction (AMI) was diagnosed in 197 individuals and 
unstable angina pectoris (UAP) in 94. AMI was diagnosed if two of the 
following criteria were fulfilled: i) typical chest pain lasting over 20 min, 
ii) ST-elevations followed by T-wave inversion or new Q-waves in the 
ECG, or iii) an increase in CK-MB to more than twice the upper limit 
of the normal value. UAP was diagnosed in patients with i) continuous 
ischemic chest pain, ii) transient or persistent ST-segment depression 
in the ECG (< 1 mm), and/or iii) elevation of CK-MB (5<CK-MB<10 
μg/l) or troponin T (0.05< TNT< 0.10 μg/l). 
Control individuals (n=314) were chosen from the same area with 
the inclusion criteria: i) no history of definite or suspected coronary 
heart disease or stroke, ii) no operations or chemotherapy within the 
previous 4 weeks, iii) no medication for diabetes, hypertension, or 
dyslipidemia, iv) no history of angina i.e. chest pain in any location 
related to exercise and relieved by rest. 
Laboratory determinations 
Sera without clot activators were collected from the patients 
within 24 hours after the diagnosis. From the controls the samples 
were collected during the home visit made by the research nurse. 
The laboratory determinations were done on frozen (-20°C) samples. 
Serum MMP-8 concentrations were determined by a time-resolved 
immunofluorometric assay (IFMA) [14]. The inter-assay coefficient 
of variation (CV) was 7.3% (n=28) and detection limit for the assay 
0.08 ng/ml. TIMP-1-ELISA (R&D Systems, Minneapolis MN, USA) 
was performed according to manufacturer’s instructions. The inter-
assay CV% was 8.2% (n=28) and the detection limit 0.08 ng/ml. For 
calculations of MMP-8 ⁄ TIMP-1 molecular ratios, the concentrations 
were converted into moles using molecular weights of 65,000 and 
28,000 g/mol for MMP-8 and TIMP-1.
Statistics
In characteristics consisting of age, total cholesterol, LDL 
cholesterol, C-reactive protein (CRP), and blood pressure values 
were normally distributed and are presented as means with standard 
deviations (SD). MMP-8 and MMP-8/TIMP-1, which displayed 
skewed distributions, are presented as medians and inter quartile 
ranges (IQR). Statistical significance of the differences in these 
parameters according to smoking status was tested by using non-
parametric Mann-Whitney test in each diagnose category. Statistical 
significance in categorical variables was tested by Chi-square test. Before 
determining the diagnostic sensitivity and specificity by receiving 
operating characteristics (ROC), MMP-8 concentrations and MMP-8/
TIMP-1 ratios were log-transformed. C-statistics was produced from 
the predicted probabilities after adjusting for age and sex. Multivariate 
logistic regression models adjusted for age and sex were used when 
determining association of MMP-8 and MMP-8/TIMP-1 levels with 
ACS separately in smokers and non-smokers. The analyses were done 
using PASW Statistics version 18.0.
Results
The characteristics of the subjects are presented according to the 
smoking status in each diagnose class in table 1. The non-smokers 
were older compared to the smokers; the differences were statistically 
significant in the ACS groups. The CRP concentrations were higher in 
the smokers than in the non-smokers both in the control and the ACS 
groups.
Medians (IQR) of serum MMP-8 concentration and MMP-8/
TIMP-1 molar ratio in each diagnose category are presented in table 
 Controls  Cases
 Non- smoking controls (n=248) 
Smoking 
controls (n=66) 
Non-smoking 
ACS (n=236)
Smoking        
ACS (n=55)
Non-smoking 
AMI (n=152)
Smoking     
AMI (n=45)
Non-smoking 
UAP (n=84)
Smoking
UAP (n=10)
Mean (SD)
Age (years) 63.4 (9.57) 61.9 (8.25) 64.2 (8.33) 56.8 (9.38) ‡ 64.6 (8.06) 56.9 (9.31) * 63.3 (8.78) 56.3 (10.19) *
Cholesterol (mmol/l) 5.77 (1.04) 5.78 (1.12) 5.34 (1.30) 5.18 (1.15) 5.35 (1.12) 5.20 (1.20) 5.32 (1.64) 5.06 (0.78)
LDL cholesterol (mmol/l) 3.69 (1.05) 3.74 (1.13) 3.40 (1.05) 3.10 (1.11) 3.50 (1.09) 3.15 (1.14) 3.13 (0.88) 2.70 (0.85)
CRP (mg/l) 2.08 (2.08) 2.96 (2.91) * 20.8 (33.5) 39.7 (61.3) * 25.8 (37.4) 46.9 (64.9) 11.9 (22.7) 3.80 (1.88)
Systolic blood pressure 
(mmHg)  -  - 140.7 (19.8) 134.3 (21.7) 140.9 (21.4) 132.9 (22.5) 140.4 (17.2) 143.3 (15.3)
Diastolic blood pressure 
(mmHg)  -  - 79.5 (11.4) 82.1 (12.8) 79.9 (12.1) 81.3 (13.5) 78.9 (10.3) 86.7 (5.77)
n (%) 
Sex (% men) 196 (79.0) 50 (75.8) 186 (78.8) 45 (81.8) 118 (77.6) 35 (77.8) 68 (81.0) 10 (100.0)
Diabetic  -  - 30 (13.2) 7 (13.0) 20 (13.6) 6 (13.6) 10 (12.3) 1 (10.0)
"Lipid lowering"-medicated  -  -   23 (15.1) 8 (17.8) 32 (40.5) 6 (60)
*p<0.05, † p<0.01, ‡ p<0.001 compared to the corresponding non-smoking category using the Mann-Whitney test for continuous variables and Chi-square test for 
categorical variables
Table 1: Characteristics of the subjects according to the smoking status.
Citation: Lahdentausta L, Sorsa T, Pussinen PJ, Pesonen E (2013) The Effect of Smoking on Diagnostic Value of Serum Matrix Metalloproteinase-8 
in Acute Coronary Syndrome. J Mol Biomark Diagn S4: 002. doi:10.4172/2155-9929.S4-002
Page 3 of 5
 J Mol Biomark Diagn      Protein & Prognostic Biomarkers           ISSN: 2155-9929 JMBD, an open access journal 
2. The smoking control subjects and the AMI patients had higher 
MMP-8 and MMP-8/TIMP-1 levels compared to the non-smoking 
subjects. The diagnostic ability of these determinations to distinguish 
the cases from the controls was analysed by the ROC separately for the 
smokers and non-smokers (Table 3). The AUCs were clearly higher in 
all comparisons for the non-smokers compared to the smokers. The 
diagnostic ability was further tested by C-statistics adjusted for age and 
sex and comparable results were obtained (Figures 1A and 1B). 
 Finally, the associations of MMP-8 concentration and MMP-
8/TIMP-1 ratio with ACS were calculated by multivariate logistic 
regression models separately for the smokers and the non-smokers 
(Table 4). The associations of both of these determinations were 
stronger in the non-smoking than in the smoking population. 
Discussion
In the present study we found that smoking significantly increases 
the serum MMP-8 concentration in generally healthy subjects and in 
patients with AMI, thereby jeopardizing its use as a diagnostic tool 
in ACS. Both the AUCs in C-statistics and the ORs in multivariate 
logistic regression models for ACS were lower in the smoking subjects 
compared to the non-smoking population. In contrary, smoking did not 
have an effect on the TIMP-1 concentration. In our earlier study with 
the same population, we showed that serum MMP-8 concentration, 
and consequently its molar ratio with TIMP-1, increased significantly 
in ACS; the increment was 2.5- and 2.1-fold compared to the healthy 
controls [13]. Furthermore, high TIMP-1 concentration, which was 
not associated with prevalent ACS, predicted ACS recurrence and 
CVD death in the follow-up [13].  Therefore, these determinations 
could be regarded as useful markers for ACS, and the factors affecting 
their diagnostic ability need to be explored. 
*p<0.05, † p<0.01, ‡ p<0.001 compared to the corresponding non-smoking 
category by Mann-Whitney test
Table 2: Median serum MMP-8 concentrations and MMP-8/TIMP-1 ratios according 
to the smoking status.
Group MMP-8 (ng/ml) MMP-8/TIMP-1 
Median (IQR)
Acute coronary syndrome
Non-smokers 117.1 (154.7) 0.34 (0.42)
Smokers 109.5 (213.6) 0.39 (0.84)
 Unstable angina
 Non-smokers 91.0 (137.4) 0.32 (0.45)
 Smokers 52.1 (44.5) * 0.16 (0.20) *
 Myocardial infraction
 Non-smokers 121.3 (147.1) 0.34 (0.42)
 Smokers 143.6 (284.4) 0.43 (0.97) ‡
Controls  
Non-smokers 41.3 (61.2) 0.14 (0.21)
Smokers 71.7 (92.0) ‡ 0.25 (0.33) ‡
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Figure 1: A and 1B: C-statistics of MMP-8 level and MMP-8/TIMP-1 ratio 
for ACS separately for smoking and non-smoking subjects. Serum MMP-
8 and TIMP-1 concentrations were determined in a case-control sample 
(n=605). The molar ratio of MMP-8 and TIMP-1 was calculated and the MMP-8 
concentrations were log-transformed. ROC analyses for ACS were performed 
using predicted probabilities produced by logistic regression models adjusted 
for age and sex. AUC, 95% CI, and p-values are presented in the figures 
shown for A) MMP-8 levels and B) MMP-8/TIMP-1 ratio.
Table 3: ROC data of serum MMP-8 concentrations and MMP-8/TIMP-1 ratio for 
ACS according to the smoking status.
Group MMP-8 (ng/ml) MMP-8/TIMP-1
Area under the curve (95% CI), p
Acute coronary syndrome
All 0.729 (0.692-0.767), <0.001 0.707 (0.668-0.746), <0.001
Non-smokers 0.750 (0.707-0.793), <0.001 0.732 (0.688-0.777), <0.001
Smokers 0.620 (0.518-0.721), 0.024 0.621 (0.520-0.722),   0.022
Unstable angina
All 0.668 (0.610-0.726), <0.001 0.660 (0.602-0.719), <0.001
Non-smokers 0.714 (0.652-0.776), <0.001 0.707 (0.643-0.771), <0.001
Smokers 0.330 (0.170-0.490), 0.085 0.341 (0.179-0.503),   0.107
Myocardial infraction
All 0.757 (0.718-0.797), <0.001 0.729 (0.686-0.770), <0.001
Non-smokers 0.771 (0.723-0.818), <0.001 0.746 (0.696-0.795), <0.001
Smokers 0.684 (0.581-0.787),   0.001 0.684 (0.582-0.786),   0.001
Table 4: Associations of serum MMP-8 concentrations and MMP-8/TIMP-1 ratios 
with ACS according to the smoking status.
Oddsratio (95% CI) 
Group logMMP-8 p value logMMP-8/TIMP-1 p value
Acute coronary syndrome
All 6.74 (4.51-10.1) <0.001 4.97 (3.42-7.23) <0.001
Non-smokers 8.06 (4.95-13.1) <0.001 6.08 (3.87-9.56) <0.001
Smokers 2.83 (1.14-7.00) 0.025 2.35 (0.98-5.64) 0.056
 Unstable angina
 All 3.73 (2.24-6.21) <0.001 3.22 (1.98-5.25) <0.001
 Non-smokers 5.35 (2.93-9.77) <0.001 4.72 (2.65-8.40) <0.001
 Smokers No determined  No determined  
 Myocardial infraction
 All 9.00 (5.64-14.4) <0.001 6.18 (4.02-9.49) <0.001
 Non-smokers 9.63 (5.45-17.0) <0.001 6.94 (4.10-11.7) <0.001
 Smokers 6.77 (2.24-20.5) 0.001 5.46 (1.91-15.6) 0.002
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Also known as collagenase-2 or neutrophil collagenase, MMP-
8 belongs to collagenase subgroup of MMPs [19]. MMP-8 can be 
expressed by a wide variety of cells including neutrophils, macrophages, 
plasma cells, T-cells, endothelial cells and fibroblasts. Regarding CVD, 
especially macrophage-associated MMP-8 is increased at rupture sites 
of abdominal aorta [20,21] which probably is reflected in the serum 
concentrations of the patients with arterial diseases [22]. Also in 
myocardial infarction the levels of MMP-8 are significantly elevated 
at the sites of affected tissue such as atheromas and carotid artery 
plaques [12,23]. Pathophysiologically, AMI and UAP have similar 
basic mechanisms; an ischemic attack of the heart muscle. However, 
a plaque rupture plays an essential role in the mechanism of AMI 
whereas its role is smaller or non-existent in some cases of UAP. 
High serum MMP-8 may be considered as a special marker of ACS 
with plaque rupture in contrast to e.g. CRP, which non-specifically 
reflects the amount of myocardial cell destruction. Undoubtedly, the 
well-known inflammatory state caused by smoking [24] was seen in the 
present study: Especially high mean CRP concentrations were observed 
in smoking AMI patient category compared to their non-smoking 
counterparts (46.9 vs. 25.8 mg/l), but a significant difference was also 
detected between the smoking and non-smoking controls. The CRP 
concentrations correlate strongly with the MMP-8 concentrations [25]. 
The smoking ACS patients had higher median MMP-8/TIMP-1 
molar ratio compared to the non-smokers. Strangely, smoking UAP 
patients had significantly lower MMP-8 and MMP-8/TIMP-1 medians 
compared to non-smoking UAP patients. The low number of smoking 
UAP patients (n=10) is the probable explanation for these findings; 
odds ratios were not possible to determine for smoking UAP patients 
because of the low number of the patient. Associations of serum 
MMP-8 concentrations and MMP-8/TIMP-1 ratios with ACS were 
substantially higher in the non-smoking population compared those 
smoking, and the same trend was seen in the AMI category. 
In addition to smoking, several other factors have been implicated 
to influence serum MMP-8 concentrations. Persons with metabolic 
syndrome have higher MMP-8 levels even in absence of diabetes or 
CVD [26].  Furthermore, patients suffering from type 2 diabetes 
combined with CVD have higher MMP-8 levels compared to non-
diabetic patients with CVD [27]. Statins reduce MMP-8 levels [28], 
thus interfering with the use of MMP-8 in the diagnostics of CVD. 
When the present patient population was collected, statins were not as 
widely used as nowadays.
Smoking can eventually disturb considerably the diagnostic 
value of serum MMP-8 analysis in CVD through several complicated 
and partly unknown mechanism. Eventually, it is also possible that 
smoking is such a strong risk factor that it diminishes other parameters 
in association studies. In conclusion, smoking can significantly disturb 
the usefulness of serum MMP-8 and MMP-8/TIMP-1 analysis as 
adjunctive diagnostic tool in CVD. 
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